Tymon Pol

Cardiologist with an special interest in heart failure. PhD. PCHF Zürich alumni. Uppsala University Hospital.

[Tymon Pol @TymonPol]

@GianluSava @HFA_President @escardio @HanCardiomd Congrats, well deserved!

[Tymon Pol @TymonPol]

Cardiomyopathies: Nationwide Trends in Prevalence, Incidence, and Mort... https://t.co/GeR8kYM7SW

[Tymon Pol @TymonPol]

Plasma Biomarkers Associated With Heart Failure Hospitalization Among Patients With Atrial Fibrillation and Subtypes of Heart Failure | Journal of the American Heart Association https://t.co/M7XwXC052l

[Tymon Pol @TymonPol]

@drjohnm Interesting results indeed - but hard to know what really drove them. Was it the modest ↑ in K⁺ (~0.3 mmol/L), or simply the well-known effects of MRAs (with potassium just a marker of exposure)?

[Tymon Pol @TymonPol]

Late gadolinium enhancement imaging and sudden cardiac death https://t.co/VVoBys4c50

[EHJ Editor-in-Chief @ehj_ed]

Integration of genetic testing into diagnostic pathways for cardiomyopathies: a clinical consensus statement by the ESC Council on Cardiovascular Genomics. Read more in EHJ
https://t.co/eQIporrZce
@ESCardio @ESC_Journals #genetic #cardiomyopathies

[Andrew P. Ambrosy, MD, MPH @AndrewPAmbrosy]

HFpEF remains a challenge: poor QoL and functional capacity. While reducing sympathetic activity, beta-blockers may worsen exercise tolerance. Evidence on outcomes is mixed, especially in HFpEF + AF. We need RCTs! Read now in #HREV (https://t.co/32R8wuo0bI). @ParagGoyalMD

[Tymon Pol @TymonPol]

Natural Course of Electrocardiographic Features in Arrhythmogenic Right Ventricular Cardiomyopathy and Their Relation to Ventricular Arrhythmic Events | Journal of the American Heart Association https://t.co/SuiSpRe2Kd

[Tymon Pol @TymonPol]

@rudyunni @drjohnm @CMichaelGibson Its already done, PMID: 39056478.

[Tymon Pol @TymonPol]

SPIRRIT-HFpEF - study design:
- First R-RCT in heart failure
- HF w/ LVEF ≥40%
- Open label spironolactone/eplerenone vs. usual care
- ~2,400 pts
- Primary outcome: CV death + total HHF
- Results expected 2026/27

https://t.co/Ak8L7WxLgs

[Tymon Pol @TymonPol]

ARAMIS - Anakinra in acute myocarditis, largest RCT in acute myocarditis. Primary EP: days alive free from any myocarditis complication

WITHDRAW-AF - withdrawal of HF-Rx in recovered AF mediated HF - can you do it?

[Tymon Pol @TymonPol]

The trials I'm looking forward to the most at #ESC2024:

FINEARTS - First MRA trial to show benefit on hard endpoints (CV death + total HF) in pts HF w/ LVEF >40%

HELIOS-B - Vutrisiran in pts w/ ATTR (wt+h). Primary EP met (all cause☠️+CV events) w/ effect on top of Tafamidis

[Giorgia Panichella @PanichellaG]

A must-read for all cardiologists: the Atlas of Regional Left Ventricular Scar in Nonischemic Cardiomyopathies is now out 🔥🔥🔥
https://t.co/6nVTqse1My

[Tymon Pol @TymonPol]

Always ask why: should genetic testing be routinely offered to all pts w/ unexplained cardiac conduction disorders with pacemaker <60yrs ? Interesting paper, worth a read👇

[Pablo Garcia-Pavia @dr_pavia]

Should patients with cardiac conduction disorders (CCD) be genetically tested? Which 🧬 should be analyzed? What is the contribution of each 🧬?
Come with me to see the results of our new study published this week @JACCJournals 👇 Long 🧵 (2/16)

[Ronald Witteles @Ron_Witteles]

🚨🚨🚨 MAJOR news in the #amyloidosis world this morning with positive topline results of #HELIOS-B. #Vutrisiran met all primary & secondary endpoints. Let's break down what we know... #StanfordAmyloidCenter (1/13)

[Translational Medicine Academy (TMA) @tmacademy_org]

Register now for the Updates in Heart Failure. Engage, learn, & connect with global peers in heart failure management! Join us in Stockholm, Sweden, on 16-17th December 2024.

#HeartFailureCongress #Medical#Cardiology

[Tymon Pol @TymonPol]

Word class update with fantastic faculty and fascinating discussions - highly recommended!

[Tymon Pol @TymonPol]

@MasriAhmadMD Intresting, so now only selecting patients with the lowest EF, possibly also hypotensive? Thats probably how they should have done GALACTIC in the first place.

[Tymon Pol @TymonPol]

@JeroenDauw @WilfriedMullens @FH_Verbrugge @piet_stinissen @pietvandervoort @ECraenenbroeck Congrats - good job! Soon perhaps you get to wear those fancy clothes too?

[Tymon Pol @TymonPol]

Sound arguments - totally agree.

[John Mandrola, MD @drjohnm]

I will start another debate on left atrial appendage occlusion. This one in Hyde Park format at #HRS2024

I have 9 reasons why I am not convinced this procedure benefits patients. This is percutaneous closure. Surgical closure was shown effective (along with AC) in LAAOS3
1/